# A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

> **NCT03207347** · PHASE2 · COMPLETED · sponsor: **University of Florida** · enrollment: 37 (actual)

## Conditions studied

- Mesothelioma
- Uveal Melanoma
- Renal Cell Carcinoma
- Cholangiocarcinoma

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT03207347
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-13
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-08-30
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207347, "A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03207347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*